News Releases
Media > News Releases > November 2011 > Attorney General DeWine Says Ohio Will Receive $23 Million in Vioxx Settlement

News Releases

Attorney General DeWine Says Ohio Will Receive $23 Million in Vioxx Settlement


(COLUMBUS, Ohio)—Ohio Attorney General Mike DeWine announced today that Ohio has joined with 42 other states and the federal government in reaching an agreement with Merck Sharp & Dohme Corp. to settle civil and criminal allegations that Merck marketed its drug Vioxx for uses not approved by the United States Food and Drug Administration (FDA), misrepresented the cardiovascular safety issues relating to the drug, and otherwise made false and misleading representations about Vioxx.  Merck will pay the states and the federal government a total of $615 million in civil damages and penalties to compensate Medicaid, Medicare, and other federal healthcare programs for harm suffered as a result of this conduct. Ohio's share of the settlement is $22,793,287.

A team appointed by the National Association of Medicaid Fraud Control Units participated in the investigation and conducted settlement negotiations with Merck on behalf of the settling states. Team members included representatives from the Offices of the Attorneys General of Ohio, Illinois, and Massachusetts.

"Making misleading statements about medications that patients expect to benefit them is not simply wrong, it's dangerous," said Attorney General DeWine. "This settlement is an important reminder to all drug companies to represent their products accurately and truthfully."

In addition, Merck has agreed to plead guilty to a violation of the Food, Drug, and Cosmetic Act and to pay a criminal fine and forfeiture of more than $300 million. The criminal component of the resolution centers on the illegal marketing and promotion of Vioxx for the treatment of rheumatoid arthritis. Vioxx was introduced into the market in 1999, but was not approved by the FDA as an indication for rheumatoid arthritis until 2002.

While it is not illegal for a physician to prescribe a drug for an unapproved use, federal law prohibits a manufacturer from promoting a drug for uses not approved by the FDA.  The civil settlements announced today are contingent upon the acceptance of Merck's guilty plea by the U.S. District Court for the District of Massachusetts.  A hearing date for this proceeding has not yet been scheduled.

Vioxx (generic name rofecoxib) is a non-steroidal anti-inflammatory medication that was approved by the FDA in 1999 for the treatment of osteoarthritis, acute pain conditions and dysmenorrhea. On Sept. 30, 2004, Merck voluntarily withdrew Vioxx from the market worldwide, citing an increase in the incidence of adverse cardiovascular events in patients taking Vioxx.

An investigation initiated by the United States Attorney's Office for the District of Massachusetts focused on allegations that Merck marketed Vioxx for the treatment of rheumatoid arthritis before the FDA approved the drug for that usage, and that Merck promoted the cardiovascular safety of Vioxx by means of certain statements and writings that were inaccurate, misleading, and inconsistent.  These allegations form the basis of the civil and criminal resolutions being announced today.

Ohio alleges that Merck made false representations concerning the safety of Vioxx to its Medicaid program and the Medicaid program relied on that information to its detriment in making formulary and prior authorization decisions with respect to the drug.

Ohio also alleges that Merck made false or misleading representations about Vioxx in its marketing, advertising, and promotion of the drug that caused physicians to write prescriptions for Vioxx that they otherwise would not have written and thereby caused the Medicaid program to pay for prescriptions that should not have been reimbursed.

As a condition of the settlement, Merck will enter into a Corporate Integrity Agreement with the United States Department of Health and Human Services, Office of the Inspector General, which will closely monitor the company's future marketing and sales practices.

– 30 –

Media Contacts:

Lisa Hackley: 614-466-3840
Mark Moretti: 614-466-3840

Bookmark and Share